» Articles » PMID: 21779514

Mutations in the P53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis

Overview
Journal Genes Cancer
Specialty Oncology
Date 2011 Jul 23
PMID 21779514
Citations 436
Authors
Affiliations
Soon will be listed here.
Abstract

Inactivation of the p53 tumor suppressor is a frequent event in tumorigenesis. In most cases, the p53 gene is mutated, giving rise to a stable mutant protein whose accumulation is regarded as a hallmark of cancer cells. Mutant p53 proteins not only lose their tumor suppressive activities but often gain additional oncogenic functions that endow cells with growth and survival advantages. Interestingly, mutations in the p53 gene were shown to occur at different phases of the multistep process of malignant transformation, thus contributing differentially to tumor initiation, promotion, aggressiveness, and metastasis. Here, the authors review the different studies on the involvement of p53 inactivation at various stages of tumorigenesis and highlight the specific contribution of p53 mutations at each phase of cancer progression.

Citing Articles

MicroRNAs in lung cancer: their role in tumor progression, biomarkers, diagnostic, prognostic, and therapeutic relevance.

Chatterjee M, Nag S, Gupta S, Mukherjee T, Shankar P, Parashar D Discov Oncol. 2025; 16(1):293.

PMID: 40067551 PMC: 11896959. DOI: 10.1007/s12672-025-02054-9.


Molecular mechanism of genetic, epigenetic, and metabolic alteration in lung cancer.

Fatima S, Kumar V, Kumar D Med Oncol. 2025; 42(3):61.

PMID: 39893601 DOI: 10.1007/s12032-025-02608-5.


Utilizing TP53 hotspot mutations as effective predictors of gemcitabine treatment outcome in non-small-cell lung cancer.

Tseng Y, Tran T, Chang J, Huang Y, Nguyen A, Yi-Feng Chang I Cell Death Discov. 2025; 11(1):26.

PMID: 39870629 PMC: 11772833. DOI: 10.1038/s41420-025-02300-7.


Impact of frequent ARID1A mutations on protein stability provides insights into cancer pathogenesis.

Goutam R, Huang G, Medina E, Ding F, Edenfield W, Sanabria H Sci Rep. 2025; 15(1):3072.

PMID: 39856215 PMC: 11760938. DOI: 10.1038/s41598-025-87103-7.


Free radicals and their impact on health and antioxidant defenses: a review.

Chandimali N, Bak S, Park E, Lim H, Won Y, Kim E Cell Death Discov. 2025; 11(1):19.

PMID: 39856066 PMC: 11760946. DOI: 10.1038/s41420-024-02278-8.


References
1.
Soussi T . p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res. 2000; 60(7):1777-88. View

2.
Adorno M, Cordenonsi M, Montagner M, Dupont S, Wong C, Hann B . A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell. 2009; 137(1):87-98. DOI: 10.1016/j.cell.2009.01.039. View

3.
Toyooka S, Tsuda T, Gazdar A . The TP53 gene, tobacco exposure, and lung cancer. Hum Mutat. 2003; 21(3):229-39. DOI: 10.1002/humu.10177. View

4.
Malkin D, Li F, Strong L, Fraumeni Jr J, Nelson C, Kim D . Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990; 250(4985):1233-8. DOI: 10.1126/science.1978757. View

5.
Donehower L, Harvey M, Slagle B, McArthur M, Montgomery Jr C, Butel J . Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992; 356(6366):215-21. DOI: 10.1038/356215a0. View